Interní Med. 2018; 20(4): 207-210 | DOI: 10.36290/int.2018.035

Edoxaban

prof. MUDr. Lenka Špinarová, Ph.D.1, prof. MUDr. Jindřich Špinar, CSc.2, doc. MUDr. Růžena Lábrová, Ph.D.2
1 I. interní kardioangiologická klinika FNUSA a LF MU Brno
2 Interní kardiologická klinika FN Brno a LF MU, Brno

Blocade of factor Xa becomes a routine part of clinical praxis instead of coumarine blockade with warfarin, providing a morebenfitial and safer effect. The main indiactions are nonvalvular atrial fibrillation, deep venous trombosis, lung embolism and inrecent time also electric cardioversion. Edoxaban appears as the fourth drug which has also evidence based data from clinicaltrials. Its advantage is also a once daily dosage.

Keywords: anticoagulation, atrial fibrillation, cardioversion, trombembolic disease, edoxaban

Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Špinarová L, Špinar J, Lábrová R. Edoxaban. Interní Med. 2018;20(4):207-210. doi: 10.36290/int.2018.035.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Laliberté F, Nelson WW., Lefebvre P. et al.: Impact of Daily Dosing Frequency on Adherence to Chronic Medications Among Nonvalvular Atrial Fibrillation Patients. Adv Ther. 2012; 29(8): 675-690. Go to original source... Go to PubMed...
    2. Lábrová R., Lábr K.: Edoxaban - farmakologický profil. Kardiol Rev Int Med 2017; 19(1): 45-50.
    3. Špinar J., Vítovec J., Špinarová L.: Edoxaban v klinických studiích. Cor et vasa 2016; 58 (6): 788-496. Go to original source...
    4. Kirchov P.,Benussi S, Dipak Kotecha D, Ahlsson A et al: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC).Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). European Heart Journal 2016; doi: 10.1093/eurheartj/ehw210 Go to original source... Go to PubMed...
    5. Gugliano RP, TIFF ChT, Braunwald E, Murphy SA, Wiwiot SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, patel SP, Patel I, Hanyck JJ, Mercuri M, Altman EM,for the Engage TIMI 48 Investigators: Edoxaban versus warfarin in Patiens with Atrial fibrillation. NEJM 2013; 369 (22): 2093-2104. Go to original source... Go to PubMed...
    6. Goette A, Merino JL, Ezekowitz M, Zamoryakhin D, Melino M, Jin J, Mercuri M, Grosso M, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot J, Lip G: Edoxaban versus enoxaparin / warfarin in subjects undergoing cardioversion of atrial fibrillation: the randomised (ENSURE-AF) study. Lancet 2016; 388 (10055): 1995-2003. Go to original source... Go to PubMed...
    7. Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406. Go to original source... Go to PubMed...
    8. Špinarová L., Špinar J.: Edoxaban-další z nových perorálních antikoagulancií. Farmakoterapeutická revue 2017: 2: 204-211.
    9. Böttger B, Thate-Waschke IM, Bauersachs R, et al: Preferences for anticoagulation therapy in atrial fibrillation: the patients' view. Journal of Thrombosis and Thrombolysis. 2015; 40(4): 406-415. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.